**Barriers and Considerations in the Extemporaneous Compounding of Omeprazole and Lansoprazole for Pediatric Patients in Public Hospital**

**Yunita Suffiana1**, Lydia Septa Desiyana2, Fitri Deliana3.

1Clinical Pharmacist, Dr. Zainoel Abidin General Hospital, Banda Aceh, Aceh, Indonesia.

2Pharmacy, University of Syiah Kuala, Banda Aceh, Aceh, Indonesia.

3PhD student at University of Western Australia

**Background and aims.** Proton pump inhibitors (PPIs) such as omeprazole and lansoprazole are commonly used to treat pediatric gastroesophageal reflux disease (GERD), particularly when compared to ranitidine in managing extra-esophageal reflux. However, tablet strengths available in Indonesia often exceed the required pediatric dose, prompting the need for alternative formulations like suspensions. Since commercial pediatric-friendly formulations are not available locally, extemporaneous suspensions must be prepared. These liquid forms, however, typically have lower stability and must be compounded upon receiving a prescription. The aim of this study is to develop a child-appropriate formulation with suitable dosage and improved palatability, and to evaluate the stability of extemporaneously prepared omeprazole and lansoprazole suspensions.

**Methods** The formulations for omeprazole 2 mg/mL and lansoprazole 3 mg/mL were adapted from Lexicomp and modified based on the availability of ingredients in Indonesia. The ingredients used included omeprazole 20 mg capsules, lansoprazole 30 mg capsules, sodium bicarbonate powder, simplex syrup, strawberry sweetening agent, sodium CMC, nipagin, nipasol, and purified water. This study employed an experimental design focusing on the formulation and stability evaluation of extemporaneously prepared liquid dosage forms. Key parameters assessed included pH, viscosity, sedimentation rate, and taste to determine the physical stability and palatability of the formulations for paediatric.

**Results.** Physical evaluation of omeprazole and lansoprazole suspensions included taste testing by 10 healthy adults, reporting a mildly sweet, slightly salty, and slightly bitter taste, overall acceptable. Omeprazole suspension showed viscosity of 91.4 mPa.s (30 rpm) and 83.9 mPa.s (60 rpm), sedimentation ratio (F) of 0.99, and pH 7.4. Lansoprazole suspension had viscosity of 78.3 mPa.s (30 rpm), 72.0 mPa.s (60 rpm), F value of 0.98, and pH 6.7.

**Conclusion.** The physical evaluation of the Omeprazole suspension formulation showed adequate viscosity and a neutral to slightly alkaline pH, indicating good stability. In contrast, the Lansoprazole suspension formulation demonstrated similarly acceptable viscosity but had a slightly alkaline pH, which may affect its stability.

**References.**

1. Boscolo, O., Perra, F., Salvo, L., Buontempo, F., & Lucangioli, S. (2020). Formulation and Stability Study of Omeprazole Oral Liquid Suspension for Pediatric Patients. *Hospital Pharmacy*, *55*(5), 314–322. <https://doi.org/10.1177/0018578719844704.>
2. Lexicomp. Lexicomp Online. Wolters Kluwer Health, 2022. Accessed [**6 January 2025**].
3. Malkawi,W.A., Alrafayah, E., AlHazabreh,M., AbuLaila,S.,& Al-Ghananeem,A.M. Formulation Challenges and Strategies to Develop Pediatric Dosage Forms. *Children* 2022, *9*(4), 488; <https://doi.org/10.3390/children9040488>.
4. Pramita G. Dwipoerwantoro, Annisa R. Yulman. The Use of Proton Pump Inhibitor Compare to that of H2–Reseptor Antagonist in a Child with Gastroesophageal Reflux Disease. *Sari Pediatri*, Vol. 20, No. 6, April 2019.

**Acknowledgement**
The authors would like to express their sincere gratitude to the Drug Formulation Laboratory, Faculty of Pharmacy, University of Syiah Kuala, for the technical assistance provided throughout this research. Special thanks are also extended to the pharmacy colleagues at Zainoel Abidin Hospital for their continuous support and collaboration during the study.